Navigation Links
AccessClosure, Inc. Marches to the Millionth Mynx!
Date:9/27/2011

MOUNTAIN VIEW, Calif., Sept. 27, 2011 /PRNewswire/ -- AccessClosure, Inc., a leading manufacturer of extravascular closure devices, announced today the shipment of its one millionth Mynx unit. The Mynx Vascular Closure Device received its FDA approval in May 2007, following with its full commercial launch in September 2007. Physician feedback attributes the achievement of this monumental milestone to the fact that the Mynx sealant is extravascular, bio-inert and non-thrombogenic, while leaving nothing behind intra-arterially.

(Logo: http://photos.prnewswire.com/prnh/20110111/SF27857LOGO)

"It is gratifying that one million patients will have benefited from the Mynx device just four and a half years after introduction to the marketplace. Excellent clinical efficacy and safety have been demonstrated with the Mynx device, and both physicians and their patients greatly appreciate the device's comfort profile," said Gregory D. Casciaro, President and CEO of AccessClosure, Inc.

In addition, increased patient comfort continues to resonate with both physicians and nurses as one of their top selection criteria in choosing the Mynx as their preferred extravascular closure device. Results from a recent prospective, randomized study indicate a significant reduction in pain with the Mynx Vascular Closure Device when compared to competitive devices. The study found that 88% of patients find closure to be the most painful part of the procedure when a competitive device was used compared to 34% of patients when the Mynx device was used.  

"Today is a monumental occasion for AccessClosure, Inc.," said Fred Khosravi, Chairman of the Board and co-founder of AccessClosure. "Vascular closure has been one of the most competitive segments in the medical device marketplace, controlled by a handful of competitors.  Not since the Mynx received its approval four years ago has any other company been so well accepted and utilized in this space. The success of Mynx is just the beginning. AccessClosure, Inc. will continue to meet the needs of its customer base for years to come with its robust product pipeline."

Also contributing to the overall success of Mynx is the continued expansion of its distribution network through international markets; demonstrated most recently with the announcement of the Biosensors International distribution agreement throughout the United Kingdom, Switzerland and France. The Mynx Device is now available through a wide global network of distributors, complementing its direct sales presence in the United States.

About AccessClosure, Inc.

Founded in 2002, AccessClosure, Inc. is a privately held medical device company pioneering innovative access site management products designed to provide a reliable, patient-friendly vascular closure experience. For more information, please visit our website at http://www.accessclosure.com/


'/>"/>
SOURCE AccessClosure, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Systech and Marchesini Showcase Complete Serialization Line at Pack Expo 2010
2. Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices
3. The SCOOTER Store Marks Half-Millionth Life Changed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):